Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This refers to a hypothesized combination of insulin lispro, a rapid-acting insulin analog, and regular human insulin, a short-acting insulin. Based on the search results, this specific combination is not a standard commercially available product and is generally not recommended for clinical use. Insulin lispro should typically not be mixed with other insulin preparations except for NPH insulin. While insulin lispro is available in premixed formulations, these combine insulin lispro with insulin lispro protamine (an intermediate-acting insulin), such as Humalog Mix 75/25 and Humalog Mix 50/50, not with regular human insulin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on insulin lispro + regular insulin.